On September 29, the 3-day the 5th China biomed innovation and investment conference came to an end.

Centered on the current hot topics, this venture capital conference deeply focused on industrial policy, global pharmaceutical research and development trends and investment and financing trends, comprehensively explored the development trend of global pharmaceutical innovation, and discussed the new development of biomedical investment cooperation.

The scene of the 5th China biomed innovation and investment conference

Shenzhen Sciencare Medical Industries Co., Ltd. （Hereinafter referred to as“sciencare medical”）With the help of the conference platform, Sciencare medical actively carried out industrial exchanges and cooperation to boost the innovation and development of medicine. The bright spots showed Sciencare medical ‘s focus and enthusiasm in the field of drug treatment.

Mr. Zhang Tao, General Manager of Sciencare Medical, delivered the roadshow report

Mr. Zhang Tao explained to the audience the development process, the project results achieved at the present stage and the future planning of Sciencare Medical Treatment. His wonderful speech won applause and positive response from the audience, and was highly concerned by the industry and investment circles at home and abroad.

As an innovative biopharmaceutical company, since its establishment in 2017, Sciencare Medical has been based in China and facing the world, focusing on scientific research and technological innovation. Scinencare Medical has been deeply engaged in the drug rehabilitation medical field for many years. Its predecessor has more than ten years of research and development foundation of drug sustained release technology. It has mastered the internationally advanced core slow and controlled release technology and has rich experience in drug research and development and clinical research.

With the cooperation and support of all parties, the 5th China biomed innovation and investment conference

has come to a successful conclusion. In the past several Venture Capital Conference, the total number of participants exceeded 10,000, known as "the most concerned pharmaceutical innovation and investment cooperation platform in the Asia-Pacific region". Sciencare Medical is very honored to receive the invitation and looks forward to participating in the next venture capital conference.